The BARDA contract supports the expansion of the SPECIFIC REVEAL™ Rapid AST System test menu to include other sample types starting with Gram-negative isolates with contract options to expand the menu to include Gram-positive blood culture and Gram-positive isolates. The contract is one component of the BARDA’s Detection Diagnostics and Devices Infrastructure Division (DDDI) medical countermeasure portfolio.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50122C0005.
Click here to read the full release or use the Request Information button below to contact bioMérieux directly.
